Trials / Completed
CompletedNCT03757325
Study to Evaluate DNL747 in Subjects With Alzheimer's Disease
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL747 in Subjects With Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Denali Therapeutics Inc. · Industry
- Sex
- All
- Age
- 55 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL747 in subjects with Alzheimer's disease when administered for 29 days in a cross-over design
Detailed description
This is a Phase 1b randomized, placebo-controlled, double-blind, crossover study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL747 in subjects with Alzheimer's disease (AD)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DNL747 | DNL747 |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2019-02-13
- Primary completion
- 2019-12-05
- Completion
- 2019-12-05
- First posted
- 2018-11-28
- Last updated
- 2020-02-26
Locations
5 sites across 2 countries: United States, Netherlands
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03757325. Inclusion in this directory is not an endorsement.